医薬品連続製造市場レポート：治療薬タイプ、製剤、用途、エンドユーザー、地域別、2024～2032年

世界の医薬品連続製造市場規模は2023年に13億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに32億米ドルに達し、2024～2032年の間に10.1%の成長率（CAGR）を示すと予測しています。効果的な医薬品生産システムに対する需要の高まり、医薬品セグメントの改善、研究開発（R&D）活動の活発化、健康への関心の高まりなどが、市場を後押しする要因のひとつです。

医薬品の連続製造は、最小限の資本投資で革新的な医薬品の品質と一貫性を向上させる、医薬品とワクチン製造への総合的なアプローチです。従来のバッチ処理とは対照的に、この方法は連続フローでシームレスに動作し、拡大性、制御性の向上、自動化、物理的介入の排除を記載しています。特筆すべきは、医薬品の連続製造は、薬剤の調合時間と人的ミスの可能性を大幅に削減し、製造プロセスの監視を強化し、製品品質が厳しい規制基準に適合することを保証することです。その結果、この技術は医薬品原薬（API）や医薬品を開発する製薬会社や製造受託機関（CMO）に広く受け入れられています。医薬品連続製造の採用は、医薬品の生産効率と規制要件への準拠を推進する上で極めて重要な役割を担っていることを裏付けています。

世界市場は、いくつかの重要な要因によって力強い成長を遂げています。特に世界の健康課題の進行に伴い、医薬品とワクチンの需要が増加しているため、業界は生産効率の改善を迫られています。連続製造はプロセスを合理化し、リードタイムを短縮し、より信頼性の高い医薬品供給を可能にするため、この需要の高まりに応える魅力的なソリューションとなっています。さらに、連続製造の費用対効果は大きな推進力となっています。従来のバッチプロセスよりも設備投資が少なくて済むため、経費を最小限に抑えながら業務の最適化を図りたい製薬企業にとっては魅力的な選択肢となります。さらに、製品の品質を高め、汚染リスクを低減し、製造プロセスをリアルタイムでモニタリングできる可能性があることから、規制当局の連続製造に対する支持も高まっています。このような規制ガイドラインとの整合性により、より多くの製薬企業が連続製造方式を採用するようになっています。さらに、より一貫性と純度の高い高品質の医薬品を製造する連続製造の能力は、極めて重要な要素です。この技術は、人的ミスを最小限に抑え、重要なパラメーターを正確に制御し、交差汚染のリスクを低減します。さらに、医薬品の連続製造は、廃棄物やエネルギー消費を最小限に抑えることで、持続可能性の目標に沿うものであり、より環境に配慮した製造プロセスを目指す企業と共鳴するものです。

医薬品連続製造市場傾向/促進要因

慢性疾患の蔓延

慢性疾患の蔓延は、市場拡大の重要な促進要因です。糖尿病、心血管疾患、各種がんなどの慢性疾患は世界的に増加しています。このような慢性的な健康問題の大幅な増加は、医薬品や薬剤に対する持続的な需要を生み出しています。連続製造は、慢性疾患に対する投薬要件の増加に対して、より効率的で迅速なソリューションを記載しています。その合理化された連続生産プロセスにより、必要不可欠な医薬品の確実で安定した供給が保証され、医薬品不足のリスクが軽減され、患者の治療へのアクセスが改善されます。さらに、製薬会社が慢性疾患用の複雑な医薬品や生物製剤の製造に努める中、連続製造は医薬品製造においてより高い管理と精度を記載しています。これは、こうした救命治療の品質と有効性を確保する上で極めて重要です。

研究開発活動の増加

研究開発（R&D）活動の重視の高まりは、医薬品連続製造の成長の強力な原動力です。製薬会社は、感染症、慢性疾患、新興の健康脅威など、さまざまな健康課題に対処するために、新薬、生物製剤、ワクチンを開発する研究開発に多額の投資を行っています。継続的製造は、より効率的で制御された製造プロセスを提供することで、こうした研究開発努力に沿うものです。製薬会社は新薬候補の製造を迅速に拡大することができ、革新的な治療法の市場投入までの時間を短縮することができます。このような生産における俊敏性は、ワクチンや治療の迅速な開発・製造が重要な、世界の健康危機やパンデミックに対応する際に特に価値があります。さらに、連続製造は、医薬品の研究開発において不可欠な製剤の最適化や、新しいドラッグデリバリー方法の探求を容易にします。製造のばらつきを抑え、重要なパラメーターを正確に制御することで、実験薬の一貫性と品質を向上させます。製薬業界が革新を続け、新たな治療法を導入する中、連続製造技術の採用は、現代の研究開発活動の要求との整合性によって後押しされ、さらに拡大すると予想されます。

人工知能（AI）ソリューションの統合の高まり

人工知能（AI）ソリューションの統合の高まりは、医薬品連続製造市場の成長を促進する有力なドライバーです。AI技術はさまざまな医薬品の研究開発、製造に革命をもたらしています。医薬品の連続製造において、AIはプロセスの最適化と自動化に利用されています。AI主導のアルゴリズムは、重要な製造パラメータをリアルタイムで監視・調整し、一貫した製品品質を確保し、逸脱のリスクを低減することができます。このレベルの自動化は効率を高め、製造プロセスにおける人的ミスを最小限に抑えます。AIは創薬や製剤にも採用されています。機械学習アルゴリズムは、膨大なデータセットを分析して潜在的な医薬品候補を特定し、その挙動を予測し、より優れた有効性と安全性のために製剤を最適化します。これにより医薬品開発が加速され、製薬会社は新しい治療法をより迅速に市場に投入できるようになります。さらに、AIを活用した予知保全は、製薬メーカーが設備の問題を事前に特定して対処し、ダウンタイムや生産中断を最小限に抑えるのに役立ちます。製薬企業が効率改善、コスト削減、製品品質向上におけるAIの可能性を認識するにつれ、継続的製造プロセスにおけるAIソリューションの採用が増加しています。このような統合は、進化する医療需要に対応するための先進技術の追求と一致し、医薬品連続製造市場の成長を促進しています。

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 世界の医薬品連続製造市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測

第6章 市場内訳：治療薬タイプ別

• 巨大分子
• 小分子

第7章 市場内訳：製剤別

• 固形製剤
• 液体と半固体製剤

第8章 市場内訳：用途別

• 最終医薬品製造
• API製造

第9章 市場内訳：エンドユーザー別

• 製薬会社
• 契約製造組織
• その他

第10章 市場内訳：地域別

• 北米
  • 米国
  • カナダ
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • オーストラリア
  • インドネシア
  • その他
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • ロシア
  • その他
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • その他
• 中東・アフリカ
  • 市場動向
  • 市場内訳：国別
  • 市場予測

第11章 SWOT分析

• 概要
• 強み
• 弱み
• 機会
• 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

• 概要
• 買い手の交渉力
• 供給企業の交渉力
• 競合の程度
• 新規参入業者の脅威
• 代替品の脅威

第14章 価格分析

第15章 競合情勢

• 市場構造
• 主要企業
• 主要企業のプロファイル
  • Baker Perkins
  • Coperion GmbH（Hillenbrand Inc.）
  • Eli Lilly and Company
  • GEA Group Aktiengesellschaft
  • Glatt GmbH
  • Korsch AG
  • Novartis AG
  • Siemens
  • SK biotek
  • Thermo Fisher Scientific Inc.
  • Viatris Inc.

List of Figures

• Figure 1: Global: Pharmaceutical Continuous Manufacturing Market: Major Drivers and Challenges
• Figure 2: Global: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Billion US$), 2018-2023
• Figure 3: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Billion US$), 2024-2032
• Figure 4: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by Therapeutics Type (in %), 2023
• Figure 5: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by Formulation (in %), 2023
• Figure 6: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by Application (in %), 2023
• Figure 7: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by End User (in %), 2023
• Figure 8: Global: Pharmaceutical Continuous Manufacturing Market: Breakup by Region (in %), 2023
• Figure 9: Global: Pharmaceutical Continuous Manufacturing (Large Molecules) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 10: Global: Pharmaceutical Continuous Manufacturing (Large Molecules) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 11: Global: Pharmaceutical Continuous Manufacturing (Small Molecules) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 12: Global: Pharmaceutical Continuous Manufacturing (Small Molecules) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 13: Global: Pharmaceutical Continuous Manufacturing (Solid Formulation) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 14: Global: Pharmaceutical Continuous Manufacturing (Solid Formulation) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 15: Global: Pharmaceutical Continuous Manufacturing (Liquid and Semi-solid Formulation) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 16: Global: Pharmaceutical Continuous Manufacturing (Liquid and Semi-solid Formulation) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 17: Global: Pharmaceutical Continuous Manufacturing (Final Drug Product Manufacturing) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 18: Global: Pharmaceutical Continuous Manufacturing (Final Drug Product Manufacturing) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 19: Global: Pharmaceutical Continuous Manufacturing (API Manufacturing) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 20: Global: Pharmaceutical Continuous Manufacturing (API Manufacturing) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 21: Global: Pharmaceutical Continuous Manufacturing (Pharmaceutical Companies) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 22: Global: Pharmaceutical Continuous Manufacturing (Pharmaceutical Companies) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 23: Global: Pharmaceutical Continuous Manufacturing (Contract Manufacturing Organizations) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 24: Global: Pharmaceutical Continuous Manufacturing (Contract Manufacturing Organizations) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 25: Global: Pharmaceutical Continuous Manufacturing (Others) Market: Sales Value (in Million US$), 2018 & 2023
• Figure 26: Global: Pharmaceutical Continuous Manufacturing (Others) Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 27: North America: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 28: North America: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 29: United States: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 30: United States: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 31: Canada: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 32: Canada: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 33: Asia-Pacific: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 34: Asia-Pacific: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 35: China: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 36: China: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 37: Japan: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 38: Japan: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 39: India: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 40: India: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 41: South Korea: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 42: South Korea: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 43: Australia: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 44: Australia: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 45: Indonesia: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 46: Indonesia: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 47: Others: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 48: Others: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 49: Europe: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 50: Europe: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 51: Germany: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 52: Germany: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 53: France: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 54: France: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 55: United Kingdom: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 56: United Kingdom: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 57: Italy: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 58: Italy: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 59: Spain: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 60: Spain: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 61: Russia: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 62: Russia: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 63: Others: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 64: Others: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 65: Latin America: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 66: Latin America: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 67: Brazil: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 68: Brazil: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 69: Mexico: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 70: Mexico: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 71: Others: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 72: Others: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 73: Middle East and Africa: Pharmaceutical Continuous Manufacturing Market: Sales Value (in Million US$), 2018 & 2023
• Figure 74: Middle East and Africa: Pharmaceutical Continuous Manufacturing Market: Breakup by Country (in %), 2023
• Figure 75: Middle East and Africa: Pharmaceutical Continuous Manufacturing Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 76: Global: Pharmaceutical Continuous Manufacturing Industry: SWOT Analysis
• Figure 77: Global: Pharmaceutical Continuous Manufacturing Industry: Value Chain Analysis
• Figure 78: Global: Pharmaceutical Continuous Manufacturing Industry: Porter's Five Forces Analysis

List of Tables

• Table 1: Global: Pharmaceutical Continuous Manufacturing Market: Key Industry Highlights, 2023 and 2032
• Table 2: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by Therapeutics Type (in Million US$), 2024-2032
• Table 3: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by Formulation (in Million US$), 2024-2032
• Table 4: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by Application (in Million US$), 2024-2032
• Table 5: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by End User (in Million US$), 2024-2032
• Table 6: Global: Pharmaceutical Continuous Manufacturing Market Forecast: Breakup by Region (in Million US$), 2024-2032
• Table 7: Global: Pharmaceutical Continuous Manufacturing Market: Competitive Structure
• Table 8: Global: Pharmaceutical Continuous Manufacturing Market: Key Players

The global pharmaceutical continuous manufacturing market size reached US$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 3.2 Billion by 2032, exhibiting a growth rate (CAGR) of 10.1% during 2024-2032. The rising demand for effective medicine production systems, the improvements in the pharmaceutical sector, the increasing research and development (R&D) activities, and the escalating health concerns are some of the factors propelling the market.

Pharmaceutical continuous manufacturing represents a holistic approach to drug and vaccine production that elevates the quality and consistency of innovative pharmaceuticals while requiring minimal capital investment. In contrast to traditional batch processing, this method operates seamlessly in a continuous flow, offering scalability, increased control, automation, and the elimination of physical interventions. Notably, continuous pharmaceutical manufacturing significantly reduces drug formulation time and the potential for human errors, enhances production process monitoring, and ensures product quality aligns with stringent regulatory standards. As a result, this technique is widely embraced by pharmaceutical companies and contract manufacturing organizations (CMOs) to develop active pharmaceutical ingredients (APIs) and medications. The adoption of pharmaceutical continuous manufacturing underscores its pivotal role in advancing pharmaceutical production efficiency and compliance with regulatory requirements.

The global market is experiencing robust growth driven by several key factors. The increasing demand for pharmaceuticals and vaccines, particularly with the ongoing global health challenges, has pressured the industry to improve production efficiency. Continuous manufacturing streamlines the process, reduces lead times, and ensures a more reliable supply of medicines, making it an attractive solution to meet this heightened demand. Furthermore, the cost-effectiveness of continuous manufacturing is a significant driver. It requires lower capital investments than traditional batch processes, making it an appealing choice for pharmaceutical companies looking to optimize their operations while minimizing expenses. Moreover, regulatory agencies are increasingly supportive of continuous manufacturing due to its potential to enhance product quality, reduce contamination risks, and provide real-time monitoring of the production process. This alignment with regulatory guidelines encourages more pharmaceutical companies to adopt continuous manufacturing practices. Additionally, the ability of continuous manufacturing to produce high-quality pharmaceuticals with greater consistency and purity is a crucial factor. This technology minimizes human errors, ensures precise control over critical parameters, and reduces the risk of cross-contamination. Besides, pharmaceutical continuous manufacturing aligns with sustainability goals by minimizing waste and energy consumption, which resonates with companies aiming for more environmentally responsible production processes.

Pharmaceutical Continuous Manufacturing Market Trends/Drivers:

The growing prevalence of several chronic ailments

The growing prevalence of chronic ailments is a significant driver behind the expanding market. Chronic diseases, such as diabetes, cardiovascular conditions, and various cancers, are rising globally. This considerable rise in chronic health issues has created a sustained demand for pharmaceuticals and medications. Continuous manufacturing offers a more efficient and responsive solution to the increasing medication requirements for chronic diseases. Its streamlined and continuous production process ensures a reliable and consistent supply of essential drugs, reducing the risk of shortages and improving patient access to treatments. Furthermore, as pharmaceutical companies strive to produce complex medications and biologics for chronic conditions, continuous manufacturing provides greater control and precision in drug production. This is crucial in ensuring the quality and efficacy of these life-saving treatments.

Increasing research and development (R&D) activities

The increasing emphasis on research and development (R&D) activities is a powerful driving force behind the growth of the pharmaceutical continuous manufacturing market. Pharmaceutical companies are investing significantly in R&D to develop new drugs, biologics, and vaccines to address various health challenges, including infectious diseases, chronic conditions, and emerging health threats. Continuous manufacturing aligns with these R&D efforts by offering a more efficient and controlled production process. It enables pharmaceutical companies to swiftly scale up the manufacturing of new drug candidates, reducing time-to-market for innovative therapies. This agility in production is particularly valuable when responding to global health crises or pandemics, where the rapid development and manufacturing of vaccines and treatments are critical. Moreover, continuous manufacturing facilitates the optimization of drug formulations and the exploration of novel drug delivery methods, both essential aspects of pharmaceutical R&D By reducing production variability and ensuring precise control over critical parameters, it enhances the consistency and quality of experimental drugs. As the pharmaceutical industry continues to innovate and introduce novel therapies, the adoption of continuous manufacturing technologies is expected to grow further, bolstered by its alignment with the demands of contemporary R&D activities.

Rising integration of artificial intelligence (AI) solutions

The rising integration of artificial intelligence (AI) solutions is a compelling driver fueling the growth of the pharmaceutical continuous manufacturing market. AI technologies are revolutionizing various pharmaceutical research, development, and manufacturing aspects. In pharmaceutical continuous manufacturing, AI is used for process optimization and automation. AI-driven algorithms can monitor and adjust critical manufacturing parameters in real time, ensuring consistent product quality and reducing the risk of deviations. This level of automation enhances efficiency and minimizes human errors in the manufacturing process. AI is also employed in drug discovery and formulation. Machine learning algorithms analyze vast datasets to identify potential drug candidates, predict their behavior, and optimize their formulations for better efficacy and safety. This accelerates drug development and enables pharmaceutical companies to bring new therapies to market more quickly. Furthermore, AI-driven predictive maintenance can help pharmaceutical manufacturers proactively identify and address equipment issues, minimizing downtime and production disruptions. As pharmaceutical companies recognize the potential of AI in improving efficiency, reducing costs, and enhancing product quality, they are increasingly adopting AI solutions in their continuous manufacturing processes. This integration aligns with the industry's pursuit of advanced technologies to meet evolving healthcare demands, thereby driving the growth of the pharmaceutical continuous manufacturing market.

Pharmaceutical Continuous Manufacturing Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global pharmaceutical continuous manufacturing market report, along with forecasts at the global, regional and country levels for 2024-2032. Our report has categorized the market based on therapeutics type, formulation, application, and end user.

Breakup by Therapeutics Type:

Large Molecules

Small Molecules

Small Molecules dominates the market

The report has provided a detailed breakup and analysis of the market based on the therapeutics type. This includes large molecules and small molecules. According to the report, small molecules represented the largest segment.

Small molecule drugs, including chemically synthesized pharmaceuticals, benefit from continuous manufacturing. It enhances the production efficiency of small molecule drugs, reduces production costs, and ensures product quality. As pharmaceutical companies seek cost-effective and efficient solutions for producing both generic and innovative small-molecule drugs, the adoption of continuous manufacturing in this segment remains robust.

Conversely, the production of large molecules, including biologics such as monoclonal antibodies and therapeutic proteins, requires highly precise and controlled manufacturing processes. Continuous manufacturing offers an advantage in producing these complex molecules with consistent quality. The biopharmaceutical industry, in particular, is increasingly turning to continuous manufacturing to meet the growing demand for biologics. This segment's adoption drives the market's growth as it aligns with the expanding biopharmaceutical sector.

Breakup by Formulation:

Solid Formulation

Liquid and Semi-solid Formulation

Solid Formulation dominates the market

The report has provided a detailed breakup and analysis of the market based on the formulation. This includes solid formulation, and liquid and semi-solid formulation. According to the report, solid formulation represented the largest segment.

Continuous manufacturing is particularly well-suited for solid dosage forms such as tablets, capsules, and powders. This segment leverages the benefits of continuous processes, including precise control over blending, granulation, and tableting. Pharmaceutical companies adopting continuous manufacturing for solid formulations experience enhanced efficiency, reduced waste, and improved consistency in producing oral solid medications. As the demand for solid dosage forms remains high, the continuous manufacturing approach significantly caters to this demand and optimizes production processes.

On the other hand, continuous manufacturing also benefits the production of liquid and semi-solid formulations, including syrups, suspensions, and creams. In this segment, continuous manufacturing streamlines mixing, blending, and filling processes. It enables pharmaceutical companies to achieve higher levels of automation, consistency, and quality control in manufacturing liquid and semi-solid medications. The adoption of continuous manufacturing in this category addresses the demand for various delivery forms and supports the development of innovative drug formulations.

Breakup by Application:

Final Drug Product Manufacturing

API Manufacturing

Final Drug Product Manufacturing dominates the market

The report has provided a detailed breakup and analysis of the market based on the application. This includes final drug product manufacturing and API manufacturing. According to the report, final drug product manufacturing represented the largest segment.

Continuous manufacturing offers a streamlined and efficient process for producing the final drug products, such as tablets, capsules, or injectables. This segment benefits from continuous processes that enhance precision and consistency in dosage form production. The adoption of continuous manufacturing in final drug product manufacturing results in cost savings, quicker time-to-market, and improved product quality, all of which drive market growth.

On the contrary, API manufacturing, the production of the active pharmaceutical ingredients that form the basis of medications, also benefits from continuous manufacturing practices. Continuous synthesis and processing of APIs ensure efficient and consistent production. Pharmaceutical companies adopting continuous manufacturing for API manufacturing experience increased yield, reduced waste, and quicker API production, thus contributing to market growth.

Breakup by End User:

Pharmaceutical Companies

Contract Manufacturing Organizations

Others

Pharmaceutical Companies dominates the market

The report has provided a detailed breakup and analysis of the market based on the end user. This includes pharmaceutical companies, contract manufacturing organizations, and others. According to the report, pharmaceutical companies represented the largest segment.

Pharmaceutical companies are major drivers of the adoption of continuous manufacturing. They utilize continuous processes for in-house production, focusing on enhancing efficiency, reducing costs, and ensuring consistent product quality. Continuous manufacturing aligns with their goal of delivering innovative, cost-effective pharmaceutical products, driving market growth.

Furthermore, contract manufacturing organizations specialize in providing manufacturing services to pharmaceutical companies, often on a contract basis. Continuous manufacturing is increasingly attractive to CMOs, enabling them to offer their clients more efficient and responsive production solutions. By adopting continuous manufacturing practices, CMOs can optimize their operations, reduce production lead times, and maintain high-quality standards, thus attracting more pharmaceutical clients and contributing to market growth.

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

North America exhibits a clear dominance, accounting for the largest market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America, comprising the United States and Canada, is a leading pharmaceutical innovation and production hub. Several factors contribute to the growth of pharmaceutical continuous manufacturing in this region. It is at the forefront of technological advancements in pharmaceutical manufacturing. Companies in this region continually invest in cutting-edge continuous manufacturing technologies, pushing the boundaries of efficiency and quality.

Regulatory bodies in North America are increasingly supportive of continuous manufacturing practices. This alignment with regulatory guidelines encourages pharmaceutical companies to adopt continuous manufacturing solutions, bolstering market growth. The region hosts numerous industry collaborations and consortiums focusing on advancing continuous manufacturing practices. These partnerships accelerate innovation and standardization within the sector.

Moreover, the pharmaceutical market in North America is vast and competitive. Companies in this region actively seek ways to improve efficiency, reduce costs, and enhance product quality, making continuous manufacturing an attractive option. Besides, pharmaceutical companies and contract manufacturing organizations have a significant global presence. Their adoption of continuous manufacturing helps disseminate these practices to other regions, further expanding the market.

Competitive Landscape:

Top companies are bolstering market growth through various strategic initiatives and innovations. They invest heavily in research and development to enhance continuous manufacturing technologies. They continually innovate and improve processes to offer more efficient, scalable, and precise manufacturing solutions. These companies collaborate closely with regulatory agencies to ensure that their continuous manufacturing processes meet the stringent requirements and quality standards set forth by regulatory bodies. This alignment instills trust and confidence in their solutions. Top firms form strategic partnerships with other pharmaceutical companies, contract manufacturers, and technology providers. These collaborations foster the development of integrated and standardized continuous manufacturing solutions that can be widely adopted across the industry. Furthermore, they offer educational resources and training programs to help pharmaceutical professionals effectively understand and implement continuous manufacturing technologies. This accelerates adoption and ensures the proper utilization of these systems. Leading companies expand internationally, addressing the global demand for advanced pharmaceutical manufacturing solutions. Their global reach helps in disseminating continuous manufacturing practices across regions.

The report has provided a comprehensive analysis of the competitive landscape in the pharmaceutical continuous manufacturing market. Detailed profiles of all major companies have also been provided.

Baker Perkins

Coperion GmbH (Hillenbrand Inc.)

Eli Lilly and Company

GEA Group Aktiengesellschaft

Glatt GmbH

Korsch AG

Novartis AG

Siemens

SK biotek

Thermo Fisher Scientific Inc.

Viatris Inc.

Recent Developments:

In 2023, Hillenbrand, Inc. successfully completed its acquisition of LINXIS Group, a leader in specialized equipment for the food, pharma, and cosmetics industries.

Eli Lilly and Company has successfully completed the acquisition of Versanis Bio in 2023, expanding its portfolio to include bimagrumab, a potential innovative treatment for obesity.

Viatris and Mapi Pharma have announced that the U.S. Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for GA Depot 40 mg, a long-acting glatiramer acetate being investigated as a once-monthly injection for the treatment of relapsing forms of multiple sclerosis (RMS). The FDA has set a target action date of March 8, 2024, for the NDA.

Key Questions Answered in This Report

• 1. How big is the global pharmaceutical continuous manufacturing market?
• 2. What is the expected growth rate of the global pharmaceutical continuous manufacturing market during 2024-2032?
• 3. What are the key factors driving the global pharmaceutical continuous manufacturing market?
• 4. What has been the impact of COVID-19 on the global pharmaceutical continuous manufacturing market?
• 5. What is the breakup of the global pharmaceutical continuous manufacturing market based on the therapeutics type?
• 6. What is the breakup of the global pharmaceutical continuous manufacturing market based on formulation?
• 7. What is the breakup of the global pharmaceutical continuous manufacturing market based on the application?
• 8. What is the breakup of the global pharmaceutical continuous manufacturing market based on the end user?
• 9. What are the key regions in the global pharmaceutical continuous manufacturing market?
• 10. Who are the key players/companies in the global pharmaceutical continuous manufacturing market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Pharmaceutical Continuous Manufacturing Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Therapeutics Type

• 6.1 Large Molecules
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Small Molecules
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Formulation

• 7.1 Solid Formulation
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Liquid and Semi-solid Formulation
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Application

• 8.1 Final Drug Product Manufacturing
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 API Manufacturing
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by End User

• 9.1 Pharmaceutical Companies
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Contract Manufacturing Organizations
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Others
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Baker Perkins
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
  • 15.3.2 Coperion GmbH (Hillenbrand Inc.)
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
  • 15.3.3 Eli Lilly and Company
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 GEA Group Aktiengesellschaft
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Glatt GmbH
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Korsch AG
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 Novartis AG
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
    • 15.3.7.3 Financials
    • 15.3.7.4 SWOT Analysis
  • 15.3.8 Siemens
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 SK biotek
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
  • 15.3.10 Thermo Fisher Scientific Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
    • 15.3.10.3 Financials
    • 15.3.10.4 SWOT Analysis
  • 15.3.11 Viatris Inc.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials